Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure). Investor presentation furnished as Exhibit 99.3 for use in upcoming company presentations.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished as Exhibit 99.3 for use in upcoming company presentations
- Presentation may provide supplementary information on INmune Bio’s strategy, programs, or outlook
Item 8.01 · Other Events
- Uniphar agreement establishes infrastructure for international access, distribution and commercialization of Ebstrocel
- Pre-MAA package submitted to UK MHRA for Ebstrocel, advancing regulatory review toward potential UK authorization
- Ebstrocel targets RDEB, a rare inherited skin disorder, supporting expansion beyond development-stage activities
- Exhibit 99.1 and 99.2 press releases contain the substantive commercial and regulatory details
Item EX-99.1 · Exhibit EX-99.1
- Master Services Agreement with Uniphar establishes international access, distribution and commercialization infrastructure for Ebstrocel
- Initial strategy: named-patient access in selected European and MENA markets before local marketing approvals
- Potential services include regulatory assessments, market access, distribution, site onboarding, pharmacovigilance and order-to-cash
- Capital-efficient outsourcing reduces need for country-by-country commercial buildout, but revenue remains contingent on regulatory and reimbursement progress
- Ebstrocel remains investigational, with UK MHRA MAA planned for 2026 and EU EMA submission planned for 2027
Item EX-99.2 · Exhibit EX-99.2
- Final pre-MAA package submitted to UK MHRA on October 20, 2026 for Ebstrocel in RDEB
- Full UK marketing application targeted for early February 2027, potentially advancing approval by approximately six weeks
- MHRA response expected three to six months after submission, subject to validation and review
- U.S. BLA submission planned for Q2 2027, with traditional or accelerated approval under consideration
- Regulatory milestones remain uncertain, with funding, manufacturing, and approval risks still material to investors
Item EX-99.3 · Exhibit EX-99.3
- Investor presentation highlights two late-stage platforms: Ebstrocel for RDEB and XPro1595 for inflammation-driven diseases
- Ebstrocel UK MAA targeted February 2027, potential approval mid-2027, with U.S. BLA planned Q2 2027
- Mission EB showed 27.5% itch reduction at month six, but primary skin-score endpoint failed at month three
- Uniphar agreement enables named-patient Ebstrocel access in selected European and MENA markets before approval
- XPro1595 strategy shifts toward TNF-driven rare diseases, potentially enabling smaller, shorter trials than Alzheimer’s development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.